Eisai and Accenture Launch Clinical Data Management in India under Global Outsourcing Agreement
News Feb 14, 2008
Eisai Co., Ltd. and Accenture Japan., Ltd. announced that under the global outsourcing agreement signed between Eisai Medical Research Inc. and Accenture LLC, Accenture will provide Eisai with clinical data management services through its delivery center in Chennai, Tamil Nadu, India.
Starting full operation from February 13, 2008 after 3 weeks trial period, the service will cover Japan, the United States, and Europe. This is the first time a major Japanese pharmaceutical company has outsourced clinical data management services as a Business Process Outsourcing to India.
Clinical data management is a set of operational activities which includes data collection, processing, preparation for analysis, and archiving of clinical trial data. Eisai is working proactively to standardize its' clinical data management process to better deliver safe and effective pharmaceuticals to patients globally.
As part of this, the company is outsourcing data management operations to Accenture's Delivery Center in India where there is a concentration of the resources, expert expertise, and appropriate technology. Going forward, Eisai intends to expand its outsourcing to include electronic data capture (eDC) in order to improve the efficiency and timeliness of data collection and reporting. This provides additional flexibility in resourcing Eisai's activities.
Eisai intends to add value through the realization of its "transformation strategy". The transformation strategy is focused on the transfer of some of the company's primary operational functions to areas with quality technology and high cost effectiveness. As a part of this strategy, Eisai established a manufacturing and research subsidiary in India in December 2007.
Through this new strategic agreement, Eisai takes an additional step toward realization of its transformation. The agreement will enhance its capabilities in global clinical research and development, reduces operational costs, and shortens the development timelines.
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE